Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Mark Stephen Huberman, M.D.

Co-Author

This page shows the publications co-authored by Mark Huberman and David M Jackman.
Connection Strength

0.210
  1. Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma. J Clin Oncol. 2009 May 20; 27(15_suppl):8065.
    View in: PubMed
    Score: 0.102
  2. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006 Jul 01; 12(13):3908-14.
    View in: PubMed
    Score: 0.084
  3. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 2008 Nov 01; 14(21):7060-7.
    View in: PubMed
    Score: 0.025
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.